Polatuzumab Vedotin Infusion

Vepotuzumab for injection

Western medicine, prescription medicine, non-medical insurance, original drug

Effects:
This product is mainly used to treat adult patients with previously untreated diffuse large B-cell lymphoma (DLBCL); and for adult patients with relapsed or refractory diffuse large B-cell lymphoma who are not suitable for hematopoietic stem cell transplantation.
Usage and Dosage:
The recommended dose of this product for patients with previously untreated diffuse large B-cell lymphoma is 1.8 mg/kg. It is administered by intravenous infusion once every 21 days (1 cycle) and combined with rituximab, cyclophosphamide, doxorubicin and prednisone (R-CHP) for 6 cycles. On the first day of each cycle, prednisone is given first, and then this product, rituximab, cyclophosphamide and doxorubicin can be given in any order. Prednisone is given on days 1 to 5 of each cycle. Rituximab monotherapy is performed in cycles 7 and 8. The recommended dose of this product for patients with relapsed or refractory diffuse large B-cell lymphoma is 1.8 mg/kg. It is administered by intravenous infusion once every 21 days (1 cycle) and is administered in combination with bendamustine and rituximab for 6 cycles. On the first day of each cycle, this product, bendamustine and rituximab can be infused in any order. Specific administration method of Urova If pre-infusion medication is not given before treatment, antihistamines and antipyretics should be given to patients at least 30 minutes before infusion of this product. The first dose of vepotuzumab is administered by 90 minutes of intravenous infusion. Patients should be monitored for infusion-related reactions during the infusion and for at least 90 minutes after the completion of the first dose. If the product was well tolerated during the previous infusion, a 30-minute infusion can be used for subsequent administration, and the patient should be monitored during the infusion and for at least 30 minutes after the completion of the infusion.
Adverse reactions:
Adverse reactions that may occur after medication include peripheral neuropathy, bone marrow suppression, infection, progressive multifocal leukoencephalopathy, hepatotoxicity, etc. In the pivotal clinical trial GO39942 (POLARIX), previously untreated DLBCL patients who received vepotuzumab combined with R-CHP (n=435) or R-CHOP (n=438) reported adverse drug reactions (ADRs) that occurred during treatment and follow-up. The most commonly reported (≥30%) ADRs (all grades) in patients treated with vepotuzumab combined with R-CHP were peripheral neuropathy (52.9%), nausea (41.6%), neutropenia (38.4%), and diarrhea (30.8%). The most common serious adverse reactions reported in ≥5% of patients were febrile neutropenia (10.6%) and infectious pneumonia (5.3%). Among patients treated with vepotuzumab plus R-CHP, an ADR leading to treatment discontinuation occurred in ≥1% of patients: pneumonia (1.1%). The safety of vepotuzumab was evaluated in 151 patients in the GO29365 study: the most commonly reported (≥30%) ADRs (all grades) in patients treated with vepotuzumab plus BR were neutropenia (45.7%), diarrhea (35.8%), nausea (33.1%), thrombocytopenia (32.5%), anemia (31.8%), and peripheral neuropathy (30.5%). Serious adverse reactions were reported in 41.7% of patients treated with vepotuzumab plus BR. The most common serious adverse reactions reported in ≥5% of patients were: febrile neutropenia (10.6%), sepsis (9.9%), pneumonia (8.6%), and fever (7.9%). Among patients treated with vepotuzumab combined with BR, the ADR leading to treatment discontinuation in >5% of patients was thrombocytopenia (7.9%).
Drug contraindications:
Contraindicated for allergic reactions to this product Use with caution during pregnancy Use with caution in early pregnancy Use with caution in late pregnancy Use with caution during lactation